Oren Livnat: Okay. And I guess, bigger picture conceptually, as you sort of lay a commercial groundwork now well ahead of potential arimoclomol approval, which is a new development in the story versus a few months ago, how do you think about the potential return on investment and shareholder value creation with OLPRUVA alone versus needing arimoclomol to layer on top of that infrastructure? I guess another way to put it, do you think do you need arimoclomol in addition to OLPRUVA to really reap the rewards of this infrastructure you’re going to build out? Or is OLPRUVA a big enough opportunity alone in your view and arimoclomol, essentially, I guess, so to be gravy, all gravy on top of that.
Neil McFarlane: Yes. Thanks, Oren. I’m going to ask Josh to take that as one of the lead architects of the acquisition team.
Joshua Schafer: Yes. And Oren, thanks again for that question. And one of the reasons why this acquisition and bringing the two companies together was so attractive for us was that we see really a standalone potential of OLPRUVA to support the build-out of a commercial team. Keep in mind, as I mentioned earlier, this is going to be a very focused and efficient team, where we’re — while we’re putting appropriate resources behind it, we’re being very prudent about how we’re doing that in a way that it’s the right investment for that opportunity. And then we can scale it as appropriate as arimoclomol and other products come on board. But the deal was structured in a way that it took into consideration the possible scenario that we were only commercializing arimoclomol, and we believe that the investment that we’re putting behind it will have an appropriate return, given the deal structure that we that we struck.
Oren Livnat: All right. And if I could just change gears to AZSTARYS, I’ve covered you guys for a long time and spent a lot of time thinking about that. And it’s ironic now that, that product has, I guess, really taken off. It’s not really the focus of your story. So as you look at that product going forward, it’s doing really well and throwing off meaningful milestones and growing royalties now. Is that something that you would look to potentially monetize for some nondilutive financing now, going — and sort of cut bait on that product and focus entirely on the orphan business or is that something that you want to maintain an ongoing relationship with Corium?
Neil McFarlane: Thanks, Oren. We’re pleased with the performance and the acceleration that’s happening at the AZSTARYS program, for sure, with our partners. In regard to financing strategies and what we might do moving forward, I’ll pass that off to LaDuane.
LaDuane Clifton: Oren, right now, I think we’re pleased in watching the progress of Corium, as Neil mentioned. And so we’re excited to continue following those trends. Our financing strategy is a bit of a broader question than just a single part of our portfolio. And I think that we’ll be evaluating all those things to make sure we have the capital we need to support Josh’s efforts to make sure each of our catalysts are met. And then ultimately, we candidly, we want to get to a point where we’re cash flow positive as a company, and we can — we’re going to continue working toward that.
Oren Livnat: All right and that’s all I probably got for now. Thank you. Good luck.
Neil McFarlane: Thank you.
Operator: Thank you. That does conclude our question-and-answer session for today. I would now like to turn the call back over to Neil McFarlane for any additional or closing remarks.
Neil McFarlane: Thank you, Todd. As we look to the end of 2023 and into 2024, we’re focused on three key priorities; first, to close the Acer acquisition and commercialize OLPRUVA for patients; second, to resubmit the arimoclomol NDA and make that product available; and third, to complete the Phase II trial in idiopathic hypersomnia and prepared to advance KP1077 with a differentiated profile into Phase III. Thank you all for your time today, and we look forward to speaking with you in the future.
Operator: This does conclude today’s Zevra Therapeutics Third Quarter 2023 Results Conference Call. You may disconnect your line at this time and have a wonderful day.
